Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports

Jpn J Clin Oncol. 2012 Feb;42(2):120-3. doi: 10.1093/jjco/hyr181. Epub 2011 Dec 23.

Abstract

Two glioblastoma multiforme patients underwent (18)F-FMISO (fluoromisonidazole) positron emission tomography study to access the tumor oxygenation status before and immediately after fractionated radiotherapy concomitant with temozolomide chemotherapy. In both cases, a prominent (18)F-FMISO tumor accumulation observed in the first study was notably decreased in the second study, which was supposed to be a reoxygenation of the tumor. As far as we investigated, this is the first report of the changes of oxygenation status in glioblastoma multiforme treated through radiation therapy with temozolomide.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents, Alkylating / therapeutic use*
  • Cell Hypoxia / drug effects
  • Cell Hypoxia / radiation effects
  • Chemoradiotherapy, Adjuvant
  • Dacarbazine / analogs & derivatives*
  • Dacarbazine / therapeutic use
  • Disease Progression
  • Dose Fractionation, Radiation*
  • Female
  • Glioblastoma / diagnostic imaging
  • Glioblastoma / drug therapy
  • Glioblastoma / metabolism*
  • Glioblastoma / radiotherapy
  • Glioblastoma / therapy*
  • Humans
  • Male
  • Middle Aged
  • Misonidazole / analogs & derivatives*
  • Oxygen / metabolism*
  • Positron-Emission Tomography* / methods
  • Radiation-Sensitizing Agents
  • Temozolomide
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Alkylating
  • Radiation-Sensitizing Agents
  • fluoromisonidazole
  • Dacarbazine
  • Misonidazole
  • Oxygen
  • Temozolomide